A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Inclusion Criteria:

- Have a diagnosis of migraine as defined by the International Headache Society
International Classification of Headache Disorders (IHS ICHD-3) beta guidelines (1.1
or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 6 months prior
to screening.

Exclusion Criteria:

- Participants who are taking, or are expected to take, therapeutic antibodies during
the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.).
Prior use of therapeutic antibodies, other than antibodies to calcitonin gene-related
peptide (CGRP) or its receptor, is allowed if that use was more than 12 months prior
to baseline.

- Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
proteins, or to galcanezumab or its excipients.

- Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor
antibody, including those who have previously completed or withdrawn from this study
or any other study investigating a CGRP antibody.

- History of persistent daily headache, cluster headache or migraine subtypes including
hemiplegic (sporadic or familial) migraine and migraine with brainstem aura
(previously basilar-type migraine) as defined by IHS ICHD-3 beta.

- History of any type of headache except for migraine, tension type headache, or
medication overuse headache, as defined by IHS ICHD-3 beta, in the 3 months prior to
randomization. For example, a history of post-traumatic headache in this 3-month
period would not be allowed.

- History of traumatic head injury, associated with significant change in the quality or
frequency of their headaches, including new onset of migraine following traumatic head
injury.

- Participants with a known history of intracranial tumors or developmental
malformations including Chiari malformations.